tbuckley/cabot-search huggingface dataset:
Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors
Authors: Melissa M Berrien-Elliott, Margery Gang, Nancy M Marin Agudelo, Lynne M Marsala, Mark Foster, Carly Neal, Wong Pamela, Wei M Meng, Maximilian M Schaettler, Tim Schappe, Todd A Fehniger
Journal: Blood (2019)
Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people
Authors: Marco Solmi, Joseph Firth, Alessandro Miola, Michele Fornaro, Elisabetta Frison, Paolo Fusar-Poli, Elena Dragioti, Jae Il Shin, Andrè F Carvalho, Brendon Stubbs, Ai Koyanagi, Steve Kisely, Christoph U Correll
Journal: The Lancet Psychiatry (2019)
Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia
Authors: Valeria Visconte, Vera Adema, Anand D. Tiwari, Cassandra M Kerr, Hassan Awada, Bartlomiej Przychodzen, Allison Noe, Rachel Toth, Christina Snider, Yvonne Parker, Yuriy Fedorov, Drew Adams, Hetty E. Carraway, Anjali S. Advani, Kevin R Kelly, Steffan T. Nawrocki, Jennifer S. Carew, Heesun J. Rogers, Daniel J. Lindner, Mikkael A. Sekeres, James G Phillips, Jaroslaw P. Maciejewski
Journal: Blood (2019)
Abstract 29: Comparison of Amiodarone versus Lidocaine for Treatment of In-Hospital Cardiac Arrest
Authors: Deborah S Wagner, Humaira Nawer, Steven L Kronick, James A Cranford, Steven M Bradley, Robert W Neumar
Journal: Circulation (2019)

Introduction: Over 200,000 patients are treated annually in the United States for in-hospital cardiac arrest (IHCA). Patients with an initial rhythm of ventricular fibrillation or pulseless ventricular tachycardia (VF/pVT) have a survival rate of less than 50%. The current American Heart Association (AHA) Advanced Cardiovascular Life Support guidelines suggest amiodarone or lidocaine as first-line agents for shock-refractory VF/pVT based on randomized clinical trials in adults with out-of-hospital cardiac arrest. Based on these results, we hypothesized that amiodarone and lidocaine have equivalent efficacy in treating hospitalized patients with VF/pVT. Methods: This is a retrospective risk-adjusted cohort study using the AHA Get with the Guidelines-Resuscitation® (GWTG-R) registry. The study included adult patients between January 1, 2000 to December 31, 2014 with IHCA due to VF/pVT that received either amiodarone or lidocaine. The primary outcome was return of spontaneous circulation (ROSC). Secondary outcomes were 24-hour survival, survival to hospital discharge, and survival with favorable neurologic outcome based on Cerebral Performance Category (CPC) 1 or 2. Results: A total of 14,630 events were included in the analysis. Among patients who met inclusion criteria, 68.7% (n=10,058) were treated with amiodarone and 31.3% (n=4,572) were treated with lidocaine. Results from multivariable logistic regression analysis showed that, controlling for 19 covariates, ROSC rates were not statistically different with lidocaine treatment vs. amiodarone (AOR = 1.02, 95% CI 0.94, 1.11). However, lidocaine treatment was associated with higher odds of a) 24-hour survival, AOR = 1.14, 95% CI 1.06, 1.23; b) survival to discharge, AOR = 1.15, 95% CI 1.06, 1.24; and c) favorable neurologic outcome at hospital discharge, AOR = 1.21, 95% CI 1.11, 1.31. Conclusion: In adult IHCA patients with VF/pVT, treatment with lidocaine compared to amiodarone was not associated with higher ROSC rates, but was associated with higher rates of survival and favorable neurological outcomes. Additional research is needed to determine the optimal antiarrhythmic therapy for VF/pVT in IHCA.
Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Authors: J. Sugisaka, S. Sugawara, Y. Toi, T. Ogasawara, M. Aso, K. Tsurumi, K. Ono, H. Shimizu, Y. Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S. Yamanda, Y. Kimura, Y. Honda
Journal: Annals of Oncology (2019)
Exertional dyspnoea–ventilation relationship to discriminate respiratory from cardiac impairment
Authors: Franciele Plachi, Fernanda Machado Balzan, Luiz Felipe Fröhlich, Ricardo Gass, Nathalia Branco Mendes, Elisa Schroeder, Danilo C. Berton, Denis E. O'Donnell, J. Alberto Neder
Journal: European Respiratory Journal (2019)

<b>An upward inflection in dyspnoea <i>versus</i> both <i>V</i>′<sub>E</sub> and WR exposes lung mechanical abnormalities. Conversely, sharp increases in dyspnoea as a function of WR but not <i>V</i>′<sub>E</sub> suggest that the underlying mechanism is proportional to inspiratory neural drive.</b>http://bit.ly/2Ogapqr
Determining Hypertrophic Cardiomyopathy Mortality
Authors: Harry Rakowski
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Frequency and severity of pain in hospitalized cancer patients at a tertiary cancer center.
Authors: Shalini Dalal, Akhila Sunkepally Reddy, Joseph Anthony Arthur, Ali Haider, Rony Dev, Janet L. Williams, Rahul Sobti, Kimberson Cochien Tanco, Eduardo Bruera
Journal: Journal of Clinical Oncology (2019)

103 Background: Recent regulations in response to the opioid crisis has presented unforeseen challenges in treating cancer patients with pain, such as frequent opioid shortages and clinicians moving away from prescribing opioids. This is especially concerning in cancer hospitals where a significant proportion of patients experience pain. Understanding the current frequency and severity of pain in hospitalized cancer patients are key hospital quality indicators, and will help in directing appropriate pain initiatives and resources. We aimed to determine the frequency, severity and changes in pain severity experienced by hospitalized cancer patients. Methods: The institutional electronic database was used to extrapolate pain scores for all cancer patients discharged over one year. The proportion of hospital-days with pain overall, on admission, and discharge is reported. A severe-pain day was a hospital-day with ≥ 1 severe pain score. A moderate-pain day was a non-severe pain day with ≥ 1 moderate pain score. Results: A total of 17097 unique patients accounted for 30056 hospital-days. Overall, the proportion of severe-, moderate-, mild-, and no pain-days was 29%, 23%, 10%, and 37% respectively. The monthly pain reports (Table) demonstrates no significant difference in pain frequency or severity over time. As compared to the first hospital-day, the proportion of severe pain days on discharge decreased from 33% to 16% (p &lt;0.01) (Medical service 28% to 16%; Pediatrics 12% to 6%, Surgical 45% to 17%). Moderate- to-severe pain days decreased from 54% to 39% (p&lt;0.01). Conclusions: A significant proportion of hospitalized cancer patients experience moderate-to-severe pain. Comprehensive assessment of the multiple dimensions of pain and strategies for early management are needed to reduce the number of moderate and severe pain days in the inpatient setting. [Table: see text]
Embedded model palliative care (PC) at a community oncology practice in central Nebraska.
Authors: Cindy Kathman, Mehmet Sitki Copur, Penny Price, Carrie Edwards, Pornchai Jonglertham, Carlene R. Springer, Colleen Vacek, Debra Reiners, Brandy Hiller-Payne, Anita Lounsbury, Tabatha Wagner, Robin Lauder, Patricia Wilson, John Mueller, Sally Molnar, Heidi DeGodt, Jessica Arbogast, Chandra Muske, Leslie Robbins, Tonya Peterson
Journal: Journal of Clinical Oncology (2019)

64 Background: PC combined with cancer care has been shown to improve patient outcomes and caregiver satisfaction while lessening unnecessary health care utilization. 85% of cancer patients receive their oncology care in the communities they live. Establishing a viable and sustainable outpatient PC service in the community oncology setting is challenging and rare nationwide. We present our 18-month PC services since its implementation at Morrison Cancer Center, a community oncology practice. Methods: Cancer patients were referred to PC by oncologists for symptom management, psychosocial support, and Advanced Care Planning (APC). PC visits were provided at the oncology clinic, home, nursing home, or hospital by our PC team (APRN, Social Workers, Chaplain and RN's). Palliative Care Prognostic Index (PPI), time to PC consultation, proportion of patients --on chemotherapy, switching to hospice care, receiving chemotherapy within the last 30 days of life, visiting ER and/or being admitted to hospital within the last 30 days of life-- were studied. Results: Over an 18-month period 72 patients were referred for a total of 470 visits. Lung, pancreas, gastroesophageal, and head and neck cancers were topmost sites. PC referrals per quarter increased from an initial 4 to an 18 at 18 months. Mean time from diagnosis to PC referral was 5.6 months (range: 1-36). Referral reasons included symptom management/support (58%), goals of care (50%), and/or predetermined triggers (15%). Mean PPI score was 50% (range 30-70). All patients had ACP. While 83% of patients were able to continue on active cancer treatment, only 5% received chemotherapy within the last 30 days of life, and 4 % had two or more ER visits with or without a hospital admission. Eventually, 17% of PC patients transitioned to hospice care. Conclusions: A PC program fostering expert symptom management, seamless communication, and trusting relationships between oncologists, palliative care team, and patients, without prematurely stopping active cancer treatments, is feasible and can be incorporated into a community oncology practice as demonstrated by the growth and success of our program. Our model may set an example for similar practices in the community oncology setting.
Tory immigration plan threatens to worsen NHS workforce crisis
Authors: Ingrid Torjesen
Journal: BMJ (2019)

The Conservative Party’s plan to increase and extend the health surcharge, the fee that immigrants pay to use the NHS, to people migrating from Europe “beggars belief” and is “ridiculously shortsighted,” health unions have warned.

The Tories have pledged to increase the charge that migrants from outside the European Economic Area must pay to use the NHS, from £400 to £625 a year, if they win the general election. When the UK leaves the EU and free movement ends the charge will be extended to immigrants from EEA countries, the party said.1 The Conservatives estimate that the measures will raise more …
The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
Authors: Hrishikesh Srinagesh, Umut Ozbek, Urvi Kapoor, Francis Ayuketang Ayuk, Mina D. Aziz, Kaitlyn Ben-David, Hannah K. Choe, Zachariah Defilipp, Aaron Etra, Stephan Grupp, Matthew Hartwell, Elizabeth O. Hexner, William J Hogan, Carrie Kitko, Steven Kowalyk, Jung-Yi Lin, Hannah Major-Monfried, Stephan Mielke, Pietro Merli, George Morales, Rainer Ordemann, Michael A. Pulsipher, Muna Qayed, Pavan Reddy, Ran Reshef, Wolf Roesler, Karamjeet S. Sandhu, Tal Schechter-Finkelstein, Jay Shah, Keith Sigel, Daniela Weber, Matthias Wölfl, Kitsada Wudhikarn, Rachel Young, John E. Levine, James L. M. Ferrara
Journal: Blood (2019)
Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial
Authors: Inés Colmegna, Mariana L Useche, Katherine Rodriguez, Deirdre McCormack, Giuliana Alfonso, Aakash Patel, Agnihotram V Ramanakumar, Elham Rahme, Sasha Bernatsky, Marie Hudson, Brian J Ward
Journal: The Lancet Rheumatology (2019)
VWF Exocytosis and Biogenesis of Weibel Palade Bodies in Endothelial Cells Are Differentially Controlled By Interactions between Bloc-2 and the Exocyst Complex
Authors: Anish V. Sharda, Joshua Harrison, Adrian R. Wilkie, Chao Fang, Lourdes M. Mendez, Joseph E. Italiano, Robert C. Flaumenhaft
Journal: Blood (2019)
Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial
Authors: Alessandro Rambaldi, Françoise Rigal-Huguet, Pavel Zak, Paul Cannell, Kun Nie, Zachary F. Zimmerman, Max S. Topp
Journal: Blood (2017)
Use of an ICU Diary and Patient Posttraumatic Stress Disorder Symptoms—Reply
Authors: Maité Garrouste-Orgeas, Sébastien Bailly, Jean-François Timsit
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Integration of specialty palliative care in a phase I ovarian cancer population.
Authors: Marisa R Moroney, Breana Hill, Jeanelle Sheeder, Jennifer Robinson Diamond, Melony Avella-Howell, Bradley Corr, Carolyn Lefkowits
Journal: Journal of Clinical Oncology (2019)

75 Background: ASCO guidelines recommend patients with advanced cancer receive early integrated specialty palliative care based on evidence of multiple clinical benefits. To our knowledge, there is no literature evaluating utilization of specialty palliative care in Phase I clinical trial patients, but there is limited data demonstrating underutilization of palliative care services in patients with life-threatening diseases including advanced cancer. Methods: A retrospective review of ovarian cancer patients enrolled in Phase I clinical trials at one institution from 2008 to 2018. Charts were reviewed for patient and disease characteristics including age, disease stage, number of chemotherapy regimens and date of death. Charts were also reviewed to determine if and when patients received specialty palliative care services. Results: A total of 121 patients with ovarian cancer were enrolled in Phase I clinical trials. Median age at time of Phase I enrollment was 59 years (range 33-88). 87% of patients had advanced stage disease: 60% Stage III and 27% Stage IV. Median number of chemotherapy regimens received prior to Phase I enrollment was 5 (range 1-13). Median survival was 311 days (95%CI 225.9-396.1). Of the 121 patients, 4 (3.3%) received specialty palliative care prior to Phase I enrollment, 7 (5.8%) within 30 days after enrollment, and 53 (43.8%) more than 30 days after enrollment. 57 patients (47.1%) never received specialty palliative care. Conclusions: Ovarian cancer patients enrolled in Phase I clinical trials have advanced cancer – defined by ASCO as disease that is late-stage and life limiting with a prognosis less than 24 months – and should therefore receive early integrated specialty palliative care. This study demonstrates that a significant portion of Phase I ovarian cancer patients are either receiving no or late integration of specialty palliative care. Further work needs to focus on increasing early integration of specialty palliative care in this population.
Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease
Authors: Yasutaka Nakashima, Yasunari Sakai, Yumi Mizuno, Kenji Furuno, Keiichi Hirono, Shinichi Takatsuki, Hiroyuki Suzuki, Yoshihiro Onouchi, Tohru Kobayashi, Kazuhiro Tanabe, Kenji Hamase, Tomofumi Miyamoto, Ryohei Aoyagi, Makoto Arita, Kenichiro Yamamura, Tamami Tanaka, Hisanori Nishio, Hidetoshi Takada, Shouichi Ohga, Toshiro Hara
Journal: Cardiovascular Research (2019)

Coronary arteritis is a life-threatening complication that may arise in the acute stage of Kawasaki disease (KD), the leading cause of systemic vasculitis in childhood. Various microorganisms and molecular pathogens have been reported to cause KD. However, little is known about the key molecules that contribute to the development of coronary arteritis in KD.To identify causative molecules for coronary arteritis in KD, we prospectively recruited 105 patients with KD and 65 disease controls in four different parts of Japan from 2015 to 2018. During this period, we conducted lipidomics analyses of their sera using liquid chromatography-mass spectrometry (LC-MS). The comprehensive LC-MS system detected a total of 27 776 molecules harbouring the unique retention time and m/z values. In the first cohort of 57 KD patients, we found that a fraction of these molecules showed enrichment patterns that varied with the sampling region and season. Among them, 28 molecules were recurrently identified in KD patients but not in controls. The second and third cohorts of 48 more patients with KD revealed that these molecules were correlated with inflammatory markers (leucocyte counts and C-reactive proteins) in the acute stage. Notably, two of these molecules (m/z values: 822.55 and 834.59) were significantly associated with the development of coronary arteritis in the acute stage of KD. Their fragmentation patterns in the tandem MS/MS analysis were consistent with those of oxidized phosphatidylcholines (PCs). Further LC-MS/MS analysis supported the concept that reactive oxygen species caused the non-selective oxidization of PCs in KD patients. In addition, the concentrations of LOX-1 ligand containing apolipoprotein B in the plasma of KD patients were significantly higher than in controls.These data suggest that inflammatory signals activated by oxidized phospholipids are involved in the pathogenesis of coronary arteritis in KD. Because the present study recruited only Japanese patients, further examinations are required to determine whether oxidized PCs might be useful biomarkers for the development of coronary arteritis in broad populations of KD.
Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
Authors: Ryan C. Lynch, Victor A. Chow, David G. Maloney, Cameron J. Turtle, Mazyar Shadman, Chaitra S. Ujjani, Ryan D. Cassaday, Brian G. Till, Yolanda D. Tseng, Edus H. Warren, Andrei R Shustov, Manoj P. Menon, Elizabeth Loggers, Jenna M. Voutsinas, Ted Gooley, Ajay K. Gopal, Stephen D. Smith
Journal: Blood (2019)
Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy
Authors: Alireza Karimian, Nathan T. Ji, Hong Song, George Sgouros
Journal: Cancer Research (2019)

Preclinical studies, in vivo, and in vitro studies, in combination with mathematical modeling can help optimize and guide the design of clinical trials. The design and optimization of alpha-particle emitter radiopharmaceutical therapy (αRPT) is especially important as αRPT has the potential for high efficacy but also high toxicity. We have developed a mathematical model that may be used to identify trial design parameters that will have the greatest impact on outcome. The model combines Gompertzian tumor growth with antibody-mediated pharmacokinetics and radiation-induced cell killing. It was validated using preclinical experimental data of antibody-mediated 213Bi and 225Ac delivery in a metastatic transgenic breast cancer model. In modeling simulations, tumor cell doubling time, administered antibody, antibody specific-activity, and antigen-site density most impacted median survival. The model was also used to investigate treatment fractionation. Depending upon the time-interval between injections, increasing the number of injections increased survival time. For example, two administrations of 200 nCi, 225Ac-labeled antibody, separated by 30 days, resulted in a simulated 31% increase in median survival over a single 400 nCi administration. If the time interval was 7 days or less, however, there was no improvement in survival; a one-day interval between injections led to a 10% reduction in median survival. Further model development and validation including the incorporation of normal tissue toxicity is necessary to properly balance efficacy with toxicity. The current model is, however, useful in helping understand preclinical results and in guiding preclinical and clinical trial design towards approaches that have the greatest likelihood of success. SIGNIFICANCE: Modeling is used to optimize αRPT.
Ageing and inequality: why do some elderly people not seek advice and help more routinely?
Authors: Simon Kenwright
Journal: BMJ (2019)

“We always end up agreeing that the alternative is worse,” writes Helen Salisbury about consultations with elderly patients who advise her not to “get old.”1 It’s a common sentiment, but perhaps Salisbury needs to improve her listening skills?

Elderly people are reputed to be more reticent about discussing suicidal …
A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Authors: F. Hayashi, H. Taniguchi, S. Takayuki, Y. Umeyama, Y. Dotsu, H. Gyotoku, H. Senju, S. Takemoto, H. Yamaguchi, S. Ono, H. Tomono, M. Shimada, H. Soda, M. Fukuda, M. Hiroshi
Journal: Annals of Oncology (2019)
Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival
Authors: Antonio Giovanni Solimando, Matteo Claudio Da Via', Patrizia Leone, Giorgio Croci, Paola Borrelli, Paula Tabares Gaviria, Andreas Brandl, Giuseppe Di Lernia, Francesco Paolo Bianchi, Silvio Tafuri, Umair Munawar, Torsten Steinbrunn, Alessandra Balduini, Assunta Melaccio, Hilka Rauert-Wunderlich, Katharina Schmiedgen, Hannah Manz, Paolo Ditonno, Roberto Ria, Erik Henke, Carolina Terragna, Wolfram Klapper, Nora Trinks, Ulrich Terpitz, Giacomo Corleone, Leo Rasche, Andreas Rosenwald, Martin Kortuem, Michele Cavo, Domenico Ribatti, Vito Racanelli, Hermann Einsele, Angelo Vacca, Andreas Beilhack
Journal: Blood (2019)
Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Authors: A. Hiura, K. Yoshino, T. Maeda, S. Oaku, K. Nagai, M. Kato, C. Yamashita, J. Uehara, Y. Fujisawa
Journal: Annals of Oncology (2019)